Traders should monitor execution on the Flyte integration and capital deployment, as well as upcoming quarterly revenue trends to confirm sustainability of growth. The dual-business model increases complexity and investor scrutiny; any signs of cash burn acceleration or delayed monetization could pressure the stock despite strong top-line momentum.
Price Chart
Executive Summary
Catheter Precision (VTAK) reported strong 2025 financial results with 95% YoY revenue growth to $819K and expanded gross margins, driven by its medical device platform. The company also announced the strategic acquisition of Flyte, a regional air mobility business, marking a major pivot into a dual-segment model spanning healthcare and aviation, supported by recent financing to strengthen its balance sheet.
Key Financial Metrics
Key Facts
- 2025 revenue increased 95% YoY to $819,000 from $420,000 in 2024
- Q4 2025 revenue grew 60% YoY to $238,000
- Gross margin improved to 92.3% in 2025 from 90.0% in 2024
- Net loss widened to $17.2M in 2025 from $16.6M in 2024, though $7.8M was non-cash
- Acquired Flyte, a revenue-generating regional air mobility company, post-year-end
- Company now operates two segments: medical devices (VIVO & LockeT) and aviation (Flyte)
- Forward-looking statements highlight liquidity risk through 2026 without additional financing
Financial Impact
Revenue nearly doubled in 2025 to $819K with high gross margins, but net losses remain substantial at $17.2M, mostly due to non-cash charges. The Flyte acquisition introduces a new revenue stream but adds execution and integration risk.
Risk Factors
- Company lacks sufficient liquidity to fund operations through 2026 without additional financing or a strategic transaction
- Integration risk from entering a completely new, capital-intensive aviation sector
- High net losses despite revenue growth, with reliance on non-cash adjustments to show improved non-GAAP performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265384 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $1.00 $0.8200 | ▲ +18.00% | ▲ +16.51% | $0.6500 (+35.00%) |
Oct 5, 2026 21d ago | Press Release | $1.62 $1.00 | ▼ −38.27% | ▼ −38.69% | $0.6500 (−59.88%) |
Oct 2, 2026 24d ago | 8-K | $1.62 $1.00 | ▼ −38.27% | ▼ −38.69% | $0.6500 (−59.88%) |
Oct 2, 2026 24d ago | Press Release | $1.62 $1.00 | ▼ −38.27% | ▼ −38.69% | $0.6500 (−59.88%) |
Sep 28, 2026 28d ago | Press Release | $0.1467 | awaiting T+5 | — | $0.6500 (+343.08%) |
Sep 25, 2026 4w ago | 8-K | $0.1467 | awaiting T+5 | — | $0.6500 (+343.08%) |
Aug 27, 2026 8w ago | Press Release | $0.2027 $0.1966 | ▼ −3.01% | ▼ −3.28% | $0.6500 (+220.67%) |
Aug 11, 2026 10w ago | Press Release | $0.2900 $0.2229 | ▼ −23.14% | ▼ −22.73% | $0.6500 (+124.14%) |
Aug 4, 2026 11w ago | Press Release | $0.2760 $0.2930 | ▲ +6.16% | ▲ +6.26% | $0.6500 (+135.51%) |
Jul 13, 2026 15w ago | EFFECT | $0.6504 $0.5020 | ▲ +22.82% | ▲ +21.87% | $0.6500 (+0.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers